There are many different types of hives -- urticaria -- with many different causes. In most cases, these puffy, red, or skin-colored bumps and wheals appear suddenly due to an allergic reaction to ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

The mainstay of treatment for urticaria is oral antihistamines as ... If possible, it is best to avoid all antihistamines in pregnancy, although none has proven teratogenic. If one is used ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

Urticaria affects 10% to 25% of the population at some point in their life (Henderson, Fleischer, & Feldman, 2000). It is characterized by short-lived swellings of the skin, mouth, and genitalia ...

Joshua Simmons, an Army colonel and physician to the vice president, also said the VP has a history of seasonal allergies and urticaria ... receiving the “optimal treatment for controlling ...

Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, Evommune, and others are evaluating new urticaria drugs to improve the treatment landscape. Promising pipeline urticaria ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Add-on dupilumab (Dupixent) significantly reduced ...

Dr. Joshua Simmons, an Army colonel and physician to the vice president, also said the vice president has a history of seasonal allergies and urticaria, or hives, which he described as ...

DelveInsight’s 'Urticaria Pipeline Insight 2024' report provides comprehensive global coverage of pipeline urticaria therapies in various stages of clinical development, major pharmaceutical companies ...

to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target ...

The rising prevalence of urticaria is fueling market growth, with increased allergic responses and lifestyle shifts playing key roles. Advances in biologic treatments and a strong development ...